Chuẩn mực mới cho liệu pháp nhắm mục tiêu trong điều trị ung thư phổi: Thời gian sống thêm không tiến triển trung bình đối với Lorlatinib ở bệnh nhân ung thư phổi không tế bào nhỏ ALK+ giai đoạn tiến triển vượt quá 5 năm – Ấn phẩm của ASCO
New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years ASCO Publications
该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Products Mentioned in This Article
These products were automatically matched from the article title, summary, and full content.
Frequently Asked Questions
Which products are related to this article?
The system matched these relevant products from the article content: LORLADX Lorlatinib、Lucius Lorlatinib – Buy Online、LORLADX Lorlatinib 100mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.